Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure
ABSTRACT A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single‐centre retrospective cohort study of adults with HCV infect...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2024-12, Vol.31 (12), p.866-872 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 872 |
|---|---|
| container_issue | 12 |
| container_start_page | 866 |
| container_title | Journal of viral hepatitis |
| container_volume | 31 |
| creator | Zhang, Helen L. Nemeth, Hayley Woodhouse, E. Wilbur Davenport, Clemontina A. Chan, Cliburn Okeke, Nwora Lance Naggie, Susanna |
| description | ABSTRACT
A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single‐centre retrospective cohort study of adults with HCV infection in the Duke University Health System who received direct‐acting antiviral therapy and achieved SVR. We performed multivariable logistic regression to assess the relationship between potential risk factors and LEE. We used generalised linear mixed‐effects models to explore longitudinal relationships between HIV and LEE. Among 1356 patients, 556 (41.0%) had LEE after achieving SVR. Higher pretreatment alanine aminotransferase (ALT) (adjusted odds ratio [aOR] 1.08 per 10 IU/L increase; 95% confidence interval [CI] 1.05–1.11) and pretreatment cirrhosis (aOR 2.26, 95% CI 1.60–3.21) were associated with higher odds of LEE; male sex was associated with lower odds of LEE (aOR 0.28, 95% CI 0.21–0.38). There was insufficient evidence of an association between HIV and LEE (aOR 0.83, 95% CI 0.47–1.44). Pretreatment ALT, cirrhosis and female sex predicted LEE in this cohort of patients with HCV infection who achieved SVR. These findings can help to identify patients at greatest risk of post‐SVR liver injury. |
| doi_str_mv | 10.1111/jvh.14009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3112529989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3130518606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2439-361d304a8b7578e57fdd0e7333d295b93e93ecc4d99721bbecdb94f82250434f3</originalsourceid><addsrcrecordid>eNp1kM9LwzAUx4Mobk4P_gMS8KKHzvxo1uY4yuaUgSK6g5fSpq-a2TUzaSfzrzdz04PgI_DeCx--JB-ETinpU19X89Vrn4aEyD3UpXwgAhZLvr-ZBQuIIGEHHTk3J4RyJugh6nDJB2TAZBc931tYZRXUCrApcVYX-EG7NzzOVGOsw6WxeKpXYPGo_lwvAI8qzzfa1HhYNv56Aku_NtrhBM-0NZV50QonrYVjdFBmlYOTXe-hp_HoMZkE07vrm2Q4DRQLuQz4gBachFmcRyKKQURlURCIOOcFkyKXHPxRKiykjBjNc1BFLsMyZsx_jIcl76GLbe7SmvcWXJMutFNQVVkNpnUpp5QJJqV30kPnf9C5aW3tX-cpTgSNvRZPXW4pZY1zFsp0afUis-uUknQjPPXC02_hnj3bJbb5Aopf8sewB662wIeuYP1_Uno7m2wjvwApJYgq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130518606</pqid></control><display><type>article</type><title>Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Zhang, Helen L. ; Nemeth, Hayley ; Woodhouse, E. Wilbur ; Davenport, Clemontina A. ; Chan, Cliburn ; Okeke, Nwora Lance ; Naggie, Susanna</creator><creatorcontrib>Zhang, Helen L. ; Nemeth, Hayley ; Woodhouse, E. Wilbur ; Davenport, Clemontina A. ; Chan, Cliburn ; Okeke, Nwora Lance ; Naggie, Susanna</creatorcontrib><description>ABSTRACT
A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single‐centre retrospective cohort study of adults with HCV infection in the Duke University Health System who received direct‐acting antiviral therapy and achieved SVR. We performed multivariable logistic regression to assess the relationship between potential risk factors and LEE. We used generalised linear mixed‐effects models to explore longitudinal relationships between HIV and LEE. Among 1356 patients, 556 (41.0%) had LEE after achieving SVR. Higher pretreatment alanine aminotransferase (ALT) (adjusted odds ratio [aOR] 1.08 per 10 IU/L increase; 95% confidence interval [CI] 1.05–1.11) and pretreatment cirrhosis (aOR 2.26, 95% CI 1.60–3.21) were associated with higher odds of LEE; male sex was associated with lower odds of LEE (aOR 0.28, 95% CI 0.21–0.38). There was insufficient evidence of an association between HIV and LEE (aOR 0.83, 95% CI 0.47–1.44). Pretreatment ALT, cirrhosis and female sex predicted LEE in this cohort of patients with HCV infection who achieved SVR. These findings can help to identify patients at greatest risk of post‐SVR liver injury.</description><identifier>ISSN: 1352-0504</identifier><identifier>ISSN: 1365-2893</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/jvh.14009</identifier><identifier>PMID: 39360629</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Alanine transaminase ; Alanine Transaminase - blood ; Antiviral agents ; Antiviral Agents - therapeutic use ; Chronic infection ; Cirrhosis ; Enzymes ; Female ; Hepacivirus - genetics ; Hepatitis C ; hepatitis C elimination ; hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Infections ; Liver ; Liver - enzymology ; Liver Cirrhosis ; liver transaminases ; Male ; Middle Aged ; Prevalence ; Regression analysis ; Retrospective Studies ; Risk Factors ; Sustained Virologic Response</subject><ispartof>Journal of viral hepatitis, 2024-12, Vol.31 (12), p.866-872</ispartof><rights>2024 John Wiley & Sons Ltd.</rights><rights>Copyright © 2024 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2439-361d304a8b7578e57fdd0e7333d295b93e93ecc4d99721bbecdb94f82250434f3</cites><orcidid>0000-0001-8285-3485</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvh.14009$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvh.14009$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39360629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Helen L.</creatorcontrib><creatorcontrib>Nemeth, Hayley</creatorcontrib><creatorcontrib>Woodhouse, E. Wilbur</creatorcontrib><creatorcontrib>Davenport, Clemontina A.</creatorcontrib><creatorcontrib>Chan, Cliburn</creatorcontrib><creatorcontrib>Okeke, Nwora Lance</creatorcontrib><creatorcontrib>Naggie, Susanna</creatorcontrib><title>Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>ABSTRACT
A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single‐centre retrospective cohort study of adults with HCV infection in the Duke University Health System who received direct‐acting antiviral therapy and achieved SVR. We performed multivariable logistic regression to assess the relationship between potential risk factors and LEE. We used generalised linear mixed‐effects models to explore longitudinal relationships between HIV and LEE. Among 1356 patients, 556 (41.0%) had LEE after achieving SVR. Higher pretreatment alanine aminotransferase (ALT) (adjusted odds ratio [aOR] 1.08 per 10 IU/L increase; 95% confidence interval [CI] 1.05–1.11) and pretreatment cirrhosis (aOR 2.26, 95% CI 1.60–3.21) were associated with higher odds of LEE; male sex was associated with lower odds of LEE (aOR 0.28, 95% CI 0.21–0.38). There was insufficient evidence of an association between HIV and LEE (aOR 0.83, 95% CI 0.47–1.44). Pretreatment ALT, cirrhosis and female sex predicted LEE in this cohort of patients with HCV infection who achieved SVR. These findings can help to identify patients at greatest risk of post‐SVR liver injury.</description><subject>Adult</subject><subject>Aged</subject><subject>Alanine transaminase</subject><subject>Alanine Transaminase - blood</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Chronic infection</subject><subject>Cirrhosis</subject><subject>Enzymes</subject><subject>Female</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>hepatitis C elimination</subject><subject>hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Liver</subject><subject>Liver - enzymology</subject><subject>Liver Cirrhosis</subject><subject>liver transaminases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sustained Virologic Response</subject><issn>1352-0504</issn><issn>1365-2893</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9LwzAUx4Mobk4P_gMS8KKHzvxo1uY4yuaUgSK6g5fSpq-a2TUzaSfzrzdz04PgI_DeCx--JB-ETinpU19X89Vrn4aEyD3UpXwgAhZLvr-ZBQuIIGEHHTk3J4RyJugh6nDJB2TAZBc931tYZRXUCrApcVYX-EG7NzzOVGOsw6WxeKpXYPGo_lwvAI8qzzfa1HhYNv56Aku_NtrhBM-0NZV50QonrYVjdFBmlYOTXe-hp_HoMZkE07vrm2Q4DRQLuQz4gBachFmcRyKKQURlURCIOOcFkyKXHPxRKiykjBjNc1BFLsMyZsx_jIcl76GLbe7SmvcWXJMutFNQVVkNpnUpp5QJJqV30kPnf9C5aW3tX-cpTgSNvRZPXW4pZY1zFsp0afUis-uUknQjPPXC02_hnj3bJbb5Aopf8sewB662wIeuYP1_Uno7m2wjvwApJYgq</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Zhang, Helen L.</creator><creator>Nemeth, Hayley</creator><creator>Woodhouse, E. Wilbur</creator><creator>Davenport, Clemontina A.</creator><creator>Chan, Cliburn</creator><creator>Okeke, Nwora Lance</creator><creator>Naggie, Susanna</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8285-3485</orcidid></search><sort><creationdate>202412</creationdate><title>Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure</title><author>Zhang, Helen L. ; Nemeth, Hayley ; Woodhouse, E. Wilbur ; Davenport, Clemontina A. ; Chan, Cliburn ; Okeke, Nwora Lance ; Naggie, Susanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2439-361d304a8b7578e57fdd0e7333d295b93e93ecc4d99721bbecdb94f82250434f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alanine transaminase</topic><topic>Alanine Transaminase - blood</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Chronic infection</topic><topic>Cirrhosis</topic><topic>Enzymes</topic><topic>Female</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>hepatitis C elimination</topic><topic>hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Liver</topic><topic>Liver - enzymology</topic><topic>Liver Cirrhosis</topic><topic>liver transaminases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sustained Virologic Response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Helen L.</creatorcontrib><creatorcontrib>Nemeth, Hayley</creatorcontrib><creatorcontrib>Woodhouse, E. Wilbur</creatorcontrib><creatorcontrib>Davenport, Clemontina A.</creatorcontrib><creatorcontrib>Chan, Cliburn</creatorcontrib><creatorcontrib>Okeke, Nwora Lance</creatorcontrib><creatorcontrib>Naggie, Susanna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Helen L.</au><au>Nemeth, Hayley</au><au>Woodhouse, E. Wilbur</au><au>Davenport, Clemontina A.</au><au>Chan, Cliburn</au><au>Okeke, Nwora Lance</au><au>Naggie, Susanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2024-12</date><risdate>2024</risdate><volume>31</volume><issue>12</issue><spage>866</spage><epage>872</epage><pages>866-872</pages><issn>1352-0504</issn><issn>1365-2893</issn><eissn>1365-2893</eissn><abstract>ABSTRACT
A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single‐centre retrospective cohort study of adults with HCV infection in the Duke University Health System who received direct‐acting antiviral therapy and achieved SVR. We performed multivariable logistic regression to assess the relationship between potential risk factors and LEE. We used generalised linear mixed‐effects models to explore longitudinal relationships between HIV and LEE. Among 1356 patients, 556 (41.0%) had LEE after achieving SVR. Higher pretreatment alanine aminotransferase (ALT) (adjusted odds ratio [aOR] 1.08 per 10 IU/L increase; 95% confidence interval [CI] 1.05–1.11) and pretreatment cirrhosis (aOR 2.26, 95% CI 1.60–3.21) were associated with higher odds of LEE; male sex was associated with lower odds of LEE (aOR 0.28, 95% CI 0.21–0.38). There was insufficient evidence of an association between HIV and LEE (aOR 0.83, 95% CI 0.47–1.44). Pretreatment ALT, cirrhosis and female sex predicted LEE in this cohort of patients with HCV infection who achieved SVR. These findings can help to identify patients at greatest risk of post‐SVR liver injury.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39360629</pmid><doi>10.1111/jvh.14009</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8285-3485</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2024-12, Vol.31 (12), p.866-872 |
| issn | 1352-0504 1365-2893 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3112529989 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Alanine transaminase Alanine Transaminase - blood Antiviral agents Antiviral Agents - therapeutic use Chronic infection Cirrhosis Enzymes Female Hepacivirus - genetics Hepatitis C hepatitis C elimination hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy HIV HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Humans Infections Liver Liver - enzymology Liver Cirrhosis liver transaminases Male Middle Aged Prevalence Regression analysis Retrospective Studies Risk Factors Sustained Virologic Response |
| title | Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A49%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20and%20Risk%20Factors%20for%20Liver%20Enzyme%20Elevation%20After%20Hepatitis%20C%20Virologic%20Cure&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Zhang,%20Helen%20L.&rft.date=2024-12&rft.volume=31&rft.issue=12&rft.spage=866&rft.epage=872&rft.pages=866-872&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/jvh.14009&rft_dat=%3Cproquest_cross%3E3130518606%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130518606&rft_id=info:pmid/39360629&rfr_iscdi=true |